Help Discover Ways to Live More Dynamically With Narcolepsy

The KYRA Study is evaluating the safety and effectiveness of an investigational drug for Narcolepsy Type 2 (NT2). During the study, participants will complete up to 10 scheduled study visits over the course of up to 25 weeks, including overnight stays. Study participation will be divided into the following periods:

Screening Period:

The screening period lasts up to 45 days before the start of study treatment. During this time, participants will undergo various tests and assessments to determine their eligibility for the study. This includes a review of medical history, a physical examination, and completion of questionnaires about sleep patterns and narcolepsy symptoms.

Study Treatment Period:

For the first part of the treatment period, participants will be randomly assigned to receive either the investigational drug or a placebo (a substance that looks like the investigational drug but does not contain any active ingredients). During the latter part of the treatment period, all participants will receive the investigational drug. Throughout the study, participants will complete various study tests and procedures.

Neither participants nor the study team will know if participants are receiving the investigational drug or a placebo during the first part of the treatment period. The treatment period will last up to 12 weeks.

Follow-Up Period:

After completing the treatment period, participants will enter a follow-up period lasting 4 weeks. During this time, participants will have 2 follow-up visits scheduled approximately 1 week and 4 weeks after their last dose of the study drug. These visits will involve monitoring health status and any potential side effects.

Long-Term Extension Period:

Participants may be invited to join a long-term extension study. If eligible, participants would receive the investigational drug for a longer duration. Participation in the extension study is voluntary. The long-term extension provides an opportunity for researchers to gather additional information about the safety and effectiveness of the investigational drug over an extended period. You can play a role in helping researchers find more ways to study and treat NT2 by participating in this clinical research study.